<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79106">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02137746</url>
  </required_header>
  <id_info>
    <org_study_id>SP010</org_study_id>
    <secondary_id>2013-003809-26</secondary_id>
    <nct_id>NCT02137746</nct_id>
  </id_info>
  <brief_title>Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer</brief_title>
  <official_title>Open-label, One-arm, Multi-centre Phase II Clinical Trial Treated With Second Cycle of Active Cellular Immunotherapy With DCVAC/PCa in Patients With Localized Prostate Cancer After Primary Radical Prostatectomy and Without Objective Progression on the First Cycle of DCVAC/PCa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotio a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotio a.s.</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of the second cycle of DCVAC/PCa in
      patients who completed the first cycle of DCVAC/PCa in the clinical trial SP003 without an
      objective progression of the disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety evaluation of the second cycle of DCVAC</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety evaluation of the second cycle of active cellular immunotherapy, which includes a second leukapheresis procedure, who after primary radical prostatectomy completed first cycle of active cellular immunotherapy in clinical trial SP003 without objective disease progression requiring additional anti-tumor therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Prostate Specific Antigen (PSA) Doubling Time</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>DCVAC/PCa Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCVAC/PCA Experimental therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/PCa</intervention_name>
    <description>DCVAC/PCa Experimental therapy</description>
    <arm_group_label>DCVAC/PCa Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male 18 years and older

          -  Histologically confirmed prostate adenocarcinoma Stage pT2

          -  Post radical Primary Prostatectomy

          -  Completion of DCVAC/PCa arm in Study SP003, without objective progression of the
             disease

        Exclusion Criteria:

          -  Prior androgen deprivation therapy for prostate cancer

          -  Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater

          -  Other uncontrolled intercurrent illness

          -  Treatment with immunotherapy against PCa

          -  Clinically significant cardiovascular disease

          -  Active autoimmune disease requiring treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Richard Kapsa</last_name>
    <phone>(+420) 2241 74448</phone>
    <email>kapsa@sotio.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Jablonec nad Nisou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Novy Jicin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>May 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Radical Prostatectomy</keyword>
  <keyword>Localized prostate cancer after primary radical prostatectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
